1. Introduction {#sec1}
===============

Current estimates indicate schistosomiasis affects over 229 million people in 78 countries ([@bib25]; [@bib43]), with *S. mansoni* and *S. haematobium* accounting for over 99.5% of human cases ([@bib20]; [@bib34]). Currently, no effective vaccine against human schistosomiasis exists and there is only one method of treatment, a single dose of praziquantel (PZQ), which is effective against all human schistosome species ([@bib41]). PZQ has few adverse side effects and, due to an expired patent, is cost effective. However, PZQ is not effective against immature parasites ([@bib31]; [@bib27]). There is concern that emergence of a PZQ resistant strain will be inevitable due to the use of mass preventive chemotherapy of PZQ ([@bib15]) and the recent efforts to increase mass treatment by 10 fold ([@bib14]) increasing selective pressure.

Previous treatments for *S. mansoni* consisted of a multitude of drugs many of which have fallen out of favor in subsequent years, due to resistance, effectiveness, cost, and side effects ([@bib11]; [@bib33]). Oxamniquine (OXA) was one such drug used extensively in Brazil ([@bib22]), where only *S. mansoni* is present, until 1996 when PZQ became the first line drug ([@bib10]). The efficacy of oxamniquine and PZQ is comparable, though in some cases OXA is more effective against *S. mansoni* when PZQ tolerance is observed ([@bib35]). OXA is only effective against *S. mansoni.* Additionally, resistance is observed in the field ([@bib9]; [@bib6]; [@bib16]; [@bib4]) and was selected for in the laboratory ([@bib29]). OXA resistant parasites exhibit as high as 500% insensitivity to the drug ([@bib42]). Previous genetic studies demonstrated that mutations in a single gene of the *S. mansoni* sulfotransferase (*Sm*SULT-OR) are responsible for OXA resistance both in the field and in lab-derived resistant isolates ([@bib7]; [@bib28]; [@bib42]; [@bib4], [@bib5]).

Sulfotransferases are enzymes that catalyze the transfer of a sulfuryl group (SO~3~) from a sulfate donor, such as 3′-phosphoadenosine-5′-phosphosulfate (PAPS), to alcohol (R--OH) or amine (R--NH~2~) acceptors in a variety of molecules to form sulfate (R-O-SO~3~^-^) or sulfo-amine (R--NH--SO~3~^-^) products, respectively. Sulfotransferases are found in both prokaryotes and eukaryotes and function in many biological processes such as growth, cell signaling, and detoxification ([@bib23]). Cytosolic sulfotransferases are involved in defense through metabolizing drugs, toxins and carcinogens, by sulfating the substrates to promote their elimination ([@bib23]; [@bib36]; [@bib2]). Sulfated substrates can result in activation of a prodrug compound into a pharmacologically active form and as a consequence these metabolites can cause pathological repercussions, including cell death ([@bib17]), as seen in the case of OXA activation within schistosome parasites ([@bib7]).

OXA is a prodrug that is enzymatically activated in the schistosome parasite ([@bib8]; [@bib42]). OXA binds to a specific *S. mansoni* sulfotransferase, known as *Sm*SULT, where it is transiently sulfated. Activated OXA subsequently binds to DNA and other macromolecules, resulting in killing of the worms ([@bib8]; [@bib42]; [@bib38]). Phylogenetic analysis of *Sm*SULT in *S. haematobium* and *S. japonicum* identified homologous sulfotransferases (*Sh*SULT and *Sj*SULT, respectively) ([@bib42]; [@bib38]). Each SULT was demonstrated to have sulfotransferase activity. Kinetic analyses allowed direct comparison of *Sm*SULT, *Sh*SULT and *Sj*SULT enzymatic activities and showed *Sm*SULT has the highest activity with OXA as substrate based on the *k*~cat~/*K*~M~ values. *Sm*SULT indicates no preference for OXA enantiomers while *Sh*SULT prefers *S*-OXA (the most potent form) and *Sj*SULT prefers *R*-OXA. Furthermore, *Sh*SULT is less active than *Sm*SULT by a factor of about one-half and *Sj*SULT is less active by about an order of magnitude. These lower levels of catalytic efficiency may explain why OXA fails to treat *S. haematobium* and *S. japonicum* infection ([@bib42]; [@bib38]). X-ray crystal structures of the three schistosomal SULTs were determined. *Sm*SULT and *Sh*SULT are 70% identical and have 3 differences in OXA contact residues based on amino acid alignment ([@bib42]). One of the differences, F39 in S. mansoni compared to Y54 S. haematobium, was predicted to cause a change in polarity of the amino acid which would negatively impact OXA binding ([@bib42]). The purpose of the present study is to ascertain if one or any combination of differences in the OXA contact residues is responsible for *S. haematobium* or *S. japonicum* inability to activate OXA.

2. Materials and methods {#sec2}
========================

2.1. Parasite life cycle and adult worm harvesting {#sec2.1}
--------------------------------------------------

Life cycles of *Schistosoma mansoni*, *S. haematobium*, *S. japonicum* and HR (an OXA resistant strain of *S. mansoni* ([@bib29])) were maintained in the laboratory. The HR mutation was demonstrated to be a glutamate 142 deletion (E142del) in a sulfotransferase enzyme ([@bib42]). Cercariae collected from previously infected *Biomphalaria glabrata*, *Bulinus truncatus* or *Oncomelania hupensis* were used to infect hamsters by wading ([@bib40]). Once the schistosome worms developed into adult worms, 30--90 days depending on the species of the parasite, the hamster hosts were euthanized and worms were obtained by perfusion ([@bib12]). Collected worms were immediately flash-frozen in liquid nitrogen and stored at −80 °C. Animal infections, perfusions and euthanasia were performed in accordance with the University of Texas Health Science Center at San Antonio IACUC protocol (UTHSCSA IACUC Protocol \#08039).

2.2. Whole worm extracts {#sec2.2}
------------------------

Aliquots of whole frozen male and female adult worms were suspended in Protease Inhibitor Cocktail (PIC) consisting of: 0.1 M HEPES pH 7.4, 0.1 mM leupeptin, 2 μM E−64, 2 μM pepstatin A, 0.1 U of aprotinin. Samples were sonicated (Qsonica) at an amplitude of 50 on ice until a fine homogenous mixture was obtained. The samples were then centrifuged at 16.1 × *g*. Supernatant was transferred to ultracentrifuge tubes and centrifuged at 69522.1 × *g* for 1 h (Beckman-Coulter Tabletop Ultracentrifuge Optima Max). Supernatant was collected; the whole soluble protein concentration was measured by NanoDrop (NanoDrop™ 1000 Spectrophotometer, Thermo Fisher) and then adjusted to 2 mg/mL using PIC.

2.3. *Sm*SULT, *Sh*SULT and *Sj*SULT proteins and mutant proteins {#sec2.3}
-----------------------------------------------------------------

Codon optimization, subcloning, mutagenesis, and expression protocols have been described elsewhere ([@bib42]; [@bib38]). The mutant proteins were *Sm*SULT: F39Y, L148I, T157S, F39Y/L149I, F39Y/T157S, F39Y/L149I/T157S; *Sh*SULT: Y45F, I158L, S166T, Y54/I158L and *Sj*SULT: V139G. Inactive *Sm*SULT-OR which has a E142del mutation served as a negative control. Recombinant proteins were then prepared for OXA activation assay by adding 1 nM from each recombinant protein to 90 μL of PIC.

2.4. Tritiated drug labeling {#sec2.4}
----------------------------

Tritiated OXA was synthesized by the Center for Innovative Drug Discovery (CIDD) using radiolabeled NaBH~4~ (Moravek Biochemicals, USA) at 100 mCi. For each mole of OXA in the aldehyde form, a single Ci was added and reacted at room temperature to completion and detected by thin layer chromatography. The levels of radioactivity were determined by blotting 10 μL of the final product onto filter paper which were then counted via liquid scintillation counter (Beckman LS 6500 Scintillation Counter, USA) for 10 min for each reaction.

2.5. OXA activation assay {#sec2.5}
-------------------------

The ability of a worm extract or a recombinant protein to activate OXA was tested by quantifying how much tritiated OXA was able to bind DNA. For each reaction, 100 μCi of ^\[3H\]^OXA was solubilized in 2 μL DMSO and added to 10 μL of a 3′-phosphoadenosine-5′-phosphosulfate (PAPS) mix containing ATP and MgCl~2~ at 50 mM each, and PAPS at 1 mM ([@bib6]). The radiolabeled OXA and PAPS mix was then added to 90 μL of either whole worm extract or recombinant protein with 10 ng/μL sheared *S. mansoni* (gDNA) as a final target for activated ^\[3H\]^OXA. The mixture was incubated at 37 °C either for 2.5 h when testing worm extract or for 5 min to 2.5 h when testing recombinant protein. Then the reaction was stopped with 3 vol of 1 mM sodium bicarbonate containing 0.1% SDS (w/v). Afterwards the reaction was extracted 3 times using 2 vol of dichloromethane. A 10 μL aliquot of the aqueous phase was collected onto a small square of filter paper in a scintillation vial and then counted via a liquid scintillation counter (Beckman LS 6500 Scintillation Counter, USA) for 10 min for each reaction.

2.6. Structure determination {#sec2.6}
----------------------------

Mutant sulfotransferase crystals, native and OXA-bound *Sm*SULT F39Y and T157S and *Sh*SULT Y54F and S166T, were prepared and X-ray crystal structures were determined as previously described ([@bib42]; [@bib38]). Data were acquired in the X-ray Crystallography Core Laboratory at the University of Texas Health Science Center at San Antonio, Advanced Photon Source Northeastern Collaborative Access Team (NE-CAT) beamline 24-ID-C or 24-ID-E and integrated and scaled using XDS ([@bib21]). Models were manually rebuilt using COOT ([@bib13]), refined using PHENIX ([@bib1]) and verified using composite omit map analysis ([@bib39]). Data collection and refinement statistics are shown in [Supplementary Table S1](#appsec1){ref-type="sec"}. Figures were generated using PyMOL (Schrödinger, LLC). Crystal structure coordinates and structure factors were deposited in the Protein Data Bank archive ([@bib44]) with entry codes 6B4X, 6B4Y, 6B4Z, 6B50, 6B51, 6B52, 6B53 and 6B54.

2.7. Amino acid alignment of *Sm*SULT, *Sh*SULT and *Sj*SULT {#sec2.7}
------------------------------------------------------------

Sequences sharing similarities with *Sm*SULT (Smp_089320) were identified in the *S. haematobium* and *S. japonicum* genomes ([@bib32]; [@bib45]). The crystallographic work performed on *Sm*SULT revealed the amino acid side chains that interact with OXA and the depleted form of PAPS, the sulfate-donating cofactor utilized by the vast majority of sulfotransferases ([@bib42]; [@bib37], [@bib38]). All the *Sm*SULT, *Sh*SULT and *Sj*SULT residues that make direct contacts with OXA or PAP at a distance of 4.5 Å were identified using PyMOL.

2.8. Statistics {#sec2.8}
---------------

Activation assay data were analyzed using R Studio or Prism (version 8). Student\'s t-tests were performed to analyze the statistical significance between samples. Wild-type *S. mansoni* serves as the positive control in OXA activation assays using worm extracts or recombinant proteins, while OXA-resistant *Sm*SULT-OR (E142del) parasites, or recombinant proteins encoded by *Sm*SULT-OR allele, were negative controls.

3. Results {#sec3}
==========

3.1. OXA worm activation assay {#sec3.1}
------------------------------

Previous studies indicated that the whole soluble protein extract from sensitive worms can activate OXA ([@bib26]). Despite having a sulfotransferase homolog, which has been shown as an active sulfotransferase *in vitro, Sh*SULT and *Sj*SULT are unable to activate OXA to a toxic level in adult worms. To confirm that resistance is present *in vitro*, 2 mg/mL whole worm extract from *S. haematobium* and *S. japonicum* were compared to 2 mg/mL whole worm extracts of OXA sensitive *S. mansoni* (Sm) and OXA resistant *S. mansoni* (E142del). Results showed high levels of OXA activation in the reaction containing sensitive *S. mansoni* extract and residual levels of OXA in the reactions containing resistant *S. mansoni* (E142del)*, S. haematobium*, and *S. japonicum* extracts ([Fig. 1](#fig1){ref-type="fig"}).Fig. 1**OXA Activation Assay on Whole Protein Extracts.**Whole worm soluble extract was obtained and diluted to a concentration of 2 mg/mL ^\[H3\]^OXA was incubated with co-factor PAPS and the extracts. Activated prodrug binds to macromolecules in the extract and remains in the aqueous phase. Unreacted radiolabeled OXA goes to the organic phase. Scintillation counts were determined after a 2.5 h incubation. The Y axis represents scintillation counts per minute (cpm). Sensitive *S. mansoni* extract is known to activate OXA and is a positive control. Resistant E142del extract is known to not activate OXA and is a negative control. Background levels of radiation were subtracted from all reactions prior to graphing. Experiments were run in triplicate.Fig. 1

Previous research identified contact residues to OXA and PAPS in *Sm*SULT (Smp_089320) ([@bib42]). An amino acid alignment between *Sm*SULT and *Sh*SULT (Sha_104171) showed 3 differences in OXA contact residues. Adding *Sj*SULT (FN317462.1) to the analysis showed that *Sj*SULT was 52% identical and 69% similar with 6 differences in OXA contact residues ([Fig. 2](#fig2){ref-type="fig"}). The PAPS contact residues were conserved for the three schistosome species ([Fig. 2](#fig2){ref-type="fig"}).Fig. 2**Amino acid alignment of *S. mansoni* SULT, *S. haematobium* SULT and *S. japonicum* SULT.**Red lines indicate residues that contact co-factor (PAPS), blue lines indicate residues that contact OXA. The green lines indicate amino acids of special interest that differ between *Sm*SULT and *Sh*SULT. The purple lines indicate amino acids that differ between *Sm*SULT and *Sj*SULT All contacts are ≤4.5 Å. *S. haematobium* SULT vs *S. mansoni* SULT: 70.6% Identity; 80.9% Similarity; *S. japonicum* SULT vs *S. mansoni* SULT: 52% Identity; 69% Similarity. Modified from [@bib42]. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)Fig. 2

3.2. X-ray crystal structures {#sec3.2}
-----------------------------

Several mutants of *Sm*SULT and *Sh*SULT were prepared to examine the impact of exchanging OXA contact residues between the species. Crystal structures for *Sm*SULT F39Y and T157S and *Sh*SULT Y54F and S166T were determined and all superimposed on their respective wild-type structures (*Sm*SULT: PDB entry 4MUA, *Sh*SULT: PDB entry 5TIV) with ≤0.32 Å root mean square deviation indicating that the mutations did not significantly distort the structures. Previous observations revealed that when a racemic mixture of OXA was soaked into *Sm*SULT or *Sh*SULT, the *S* enantiomer binds preferentially ([@bib37], [@bib38]). Likewise, all crystallized mutants bound *S*-OXA from soaks with a racemic mixture ([Supplementary Fig. S1](#appsec1){ref-type="sec"}). Furthermore, the *Sh*SULT tyrosine substitution for phenylalanine in *Sm*SULT and its position in the active site was found to allow more than one binding mode for OXA in *Sh*SULT ([@bib38]). This observation was duplicated in the F↔Y mutants where OXA bound in *Sm*SULT F39Y shifted into the "*haematobium*-like" binding position and in *Sh*SULT Y54F, OXA shifted into the "*mansoni*-like" binding position ([Fig. 3](#fig3){ref-type="fig"}A). Clearly, exchanging tyrosine for phenylalanine at this position in *Sh*SULT (and possibly *Sj*SULT) does not prevent OXA binding, but it does have an impact by allowing multiple OXA positions in the active site unlike the fixed OXA position in *Sm*SULT. In *Sm*SULT T157S and *Sh*SULT S166T structures, OXA bound in the positions observed for their wild-type OXA complex structures ([Fig. 3](#fig3){ref-type="fig"}B and C).Fig. 3**Structural depiction of amino acid differences between *Sm*SULT, *Sh*SULT and *Sj*SULT.**A) OXA-bound *Sm*SULT (yellow) superimposed on OXA-bound *Sh*SULT (gray). Three critical OXA contact residues from *Sm*SULT (L149, F39, T157) are shown as sticks along with *Sh*SULT counterparts (I158, Y54, S166). OXA, PAP and catalytic D91 (*Sm*SULT) and D100 (*Sh*SULT) are also shown in stick representation. Note the slightly different positions of OXA when bound in *Sm*SULT (yellow) and *Sh*SULT (gray). **B)** OXA bound in *Sh*SULT S166T (light blue) and *Sm*SULT Y54F (dark green) adopts the position of OXA-bound wild-type *Sh*SULT shown in panel A. **C)** OXA bound in *Sh*SULT Y54F (cyan) and *Sm*SULT T157S (green) adopts the position of OXA-bound wild-type *Sm*SULT shown in panel A. **D)** Crystal structure of *Sj*SULT (PDB entry 5TIZ) with OXA (cyan) superimposed on the active site. *Sj*SULT amino acid labels are shown in black and equivalent *Sm*SULT amino acids are shown in blue. The V139 side chain of *Sj*SULT creates a steric clash with OXA (at top) if it were to bind in the same position and conformation observed for OXA-bound *Sm*SULT or *Sh*SULT. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)Fig. 3

3.3. OXA recombinant protein activation assay {#sec3.3}
---------------------------------------------

We repeated activation assays using recombinant proteins, rather than whole worm extracts. We observed that recombinant proteins from *S. mansoni* and *S. haematobium* (r*Sm*SULT and r*Sh*SULT) both showed strong OXA activation compared to the r*Sm*SULT-OR (E142del). Consistent with this, we found that introducing *S. haematobium* residues into *S. mansoni* recombinant proteins, or *S. haematobium* residues into *S. mansoni*, had no impact on activation activity. The mutations to interconvert *Sm*SULT and *Sh*SULT are *Sm*SULT F39Y, L149I, T157S and *Sh*SULT Y54F, I158L, S166T ([Fig. 4](#fig4){ref-type="fig"}). Single, double and triple mutant proteins to interconvert r*Sm*SULT and r*Sh*SULT showed no effect on the ability of the recombinant sulfotransferase to activate OXA ([Fig. 4](#fig4){ref-type="fig"}, [Fig. 5](#fig5){ref-type="fig"}, [Fig. 6](#fig6){ref-type="fig"}). Therefore, our working hypothesis predicting the differences in contact residues between *Sm*SULT and *Sh*SULT are responsible for the OXA resistance exhibited by *S. haematobium* does not explain the natural resistance of the *S. haematobium* worms to OXA.Fig. 4***Sm*SULT Mutants in Recombinant Protein OXA Activation Assay.**Purified recombinant proteins were incubated with ^\[3H\]^OXA and the co-factor PAPS. Activated prodrug binds to sheared gDNA added to the mix and remains in the aqueous phase. Unreacted radiolabeled OXA goes to the organic phase. Scintillation counts were determined after a 2.5 h incubation. The Y axis represents scintillation counts per minute (cpm). r*Sm*SULT is known to activate OXA and is a positive control. E142del is known to not activate OXA and is a negative control. Background levels of radiation were subtracted from all reactions prior to graphing. Experiments were run in triplicate.Fig. 4Fig. 5***Sh*SULT Mutants in Recombinant Protein OXA Activation Assay.**^\[3H\]^OXA was incubated with co-factor PAPS and the recombinant proteins. Activated prodrug binds to sheared gDNA added to the mix and remains in the aqueous phase. Unreacted radiolabeled OXA goes to the organic phase. Scintillation counts were determined after a 2.5 h incubation. The Y axis represents scintillation counts per minute (cpm). Higher OXA activation is indicated by higher cpm. r*Sm*SULT is known to activate OXA and is a positive control. E142del is known to not activate OXA and is a negative control. Background levels of radiation were subtracted from all reactions prior to graphing. Experiments were run in triplicate.Fig. 5Fig. 6***Sm*SULT and *Sh*SULT Mutants in Recombinant Protein OXA Activation Assay.**^\[3H\]^OXA was incubated with co-factor PAPS and the recombinant proteins. Activated prodrug binds to sheared gDNA added to the mix and remains in the aqueous phase. Unreacted radiolabeled OXA will go to the organic phase. Scintillation counts were determined after a 2.5 h incubation. The Y axis represents scintillation counts per minute (cpm). Higher OXA activation is indicated by higher cpm. r*Sm*SULT is known to activate OXA and is a positive control. E142del is known to not activate OXA and is a negative control. Background levels of radiation were subtracted from all reactions prior to graphing. Experiments were run in triplicate.Fig. 6

In the case of *S. japonicum*, r*Sj*SULT failed to activate OXA. Our previous studies suggested that a glycine to valine change at residue 139 might account for the inability of *Sj*SULT to activate OXA ([Fig. 3](#fig3){ref-type="fig"}D) ([@bib38]). We made the mutation and tested the ability of the Val139Gly mutation to activate OXA in a recombinant protein activation assay. The mutation results in an approximate 10-fold increase in activation of OXA ([Fig. 7](#fig7){ref-type="fig"}), indicating that *Sj*SULT Val139 can account in part for the lack of *Sj*SULT\'s activation of OXA. These results are consistent with the hypothesis that amino acid changes are, in part, responsible for the lack of OXA activation in *S. japonicum*.Fig. 7***Sj*SULT Mutant in Recombinant Protein OXA Activation Assay**.^\[3H\]^OXA was incubated with co-factor PAPS and the recombinant protein. Activated prodrug binds to sheared gDNA added to the mix and remains in the aqueous phase. Unreacted radiolabeled OXA goes to the organic phase. Scintillation counts were determined after stopping the reaction in 2.5 hr. The Y axis represents scintillation counts per minute (cpm). Background levels of radiation were subtracted from all reactions prior to graphing. Experiments were run in triplicate.Fig. 7

Since the OXA activation assay determines an endpoint in an *in vitro* setting, it is possible that the results are an artifact of the long incubation and high protein concentrations. If efficiency of the sulfotransferase in *Sh*SULT is significantly delayed compared to *Sm*SULT it may account for OXA resistance. To determine if sulfotransferase efficiency is the reason for *S. haematobium* resistance to OXA, we measured activation at 15 min intervals over the 2.5 h incubation. There was little difference at most of the time points except for the first 30 min ([Fig. 8](#fig8){ref-type="fig"}A). To better define the difference, we repeated this experiment using 5 min increments over 1 h. Results again showed marginal statistically significant OXA activation at between 25 min and 45 min (P = 0.018), however, the reactions all plateau by the 1 h mark ([Fig. 8](#fig8){ref-type="fig"}B).Fig. 8**Recombinant Protein OXA Activation Assay at 15 (A) and 5 min (B) Time Points.**^\[3H\]^OXA was incubated with co-factor PAPS and the recombinant proteins. Activated prodrug binds to sheared gDNA added to the mix and remains in the aqueous phase. Unreacted radiolabeled OXA goes to the organic phase. Scintillation counts were determined after stopping the reaction in 15 (A) or 5 min (B) increments. The Y axis represents scintillation counts per minute (cpm). Background levels of radiation were subtracted from all reactions prior to graphing. Experiments were run in triplicate.Fig. 8

An alternative hypothesis could be the presence of a component in the *S. haematobium* whole worm extract that inhibits *Sh*SULT. To determine if *Sm*SULT could complement OXA activation in *S. haematobium* extracts, each of the whole worm extracts -- sensitive *S. mansoni*, resistant *S. mansoni* (E142del) and *S. haematobium* -- were supplemented with varying amounts of r*Sm*SULT from 1 μM to 100 fM. At high concentrations -- from 100 nM to 1 μM of r*Sm*SULT -- all of the extracts activated OXA equally. However, when 10 nM of r*Sm*SULT was added, the E142del extract showed the same levels of OXA activation as *S. mansoni* extract but the *S. haematobium* extract showed background levels ([Fig. 9](#fig9){ref-type="fig"}). At 1 nM, *Sh*SULT is no longer complemented by *Sm*SULT and at 1 pM E142del is still complemented by *Sm*SULT.Fig. 9**r*****Sm*****SULT Titration Assay.**Fresh worm extracts of *S. mansoni*, *S. mansoni* E142del and *S. haematobium* were made (2 mg/mL) and incubated with varying amounts of r*Sm*SULT. Scintillation counts were determined after a 2.5 h incubation. The Y axis represents scintillation counts per minute (cpm). Unsupplemented extracts acted as internal controls. Background levels of radiation were subtracted from all reactions prior to graphing. Experiments were run in triplicate.Fig. 9

4. Discussion {#sec4}
=============

Oxamniquine kills *S. mansoni*, but not *S. haematobium* and *S. japonicum*. We previously hypothesized that amino acid and resulting structural differences between *Sm*SULT and *Sh*SULT or *Sj*SULT would explain the specificity of the drug towards *S. mansoni* ([@bib42]). These experiments were designed to test this hypothesis.

4.1. Do amino acid changes in schistosome sulfotransferase explain species specific drug action? {#sec4.1}
------------------------------------------------------------------------------------------------

Initially, we used OXA activation assay using the soluble fraction from whole worm extracts incubated with ^\[3H\]^OXA to quantify OXA activation after 2.5 h. This end point assay used conditions of saturation for all elements except for the endogenous sulfotransferase protein present in the extracts. Previous studies showed OXA sensitive *S. mansoni* extract caused high levels of OXA activation based on scintillation counts of the aqueous phase. These results closely parallel killing activity against adult worms. We observed that extracts from OXA-sensitive *S. mansoni* showed strong OXA activation activity, while extracts from OXA resistant *S. mansoni, S. haematobium* and *S. japonicum* extracts showed low to background levels of OXA activation based on scintillation counts in the aqueous phase ([Fig. 1](#fig1){ref-type="fig"}).

To investigate sulfotransferases in a controlled environment, a recombinant protein OXA activation assay was developed. The recombinant protein OXA activation assay eliminates the use of whole soluble worm extract and replaces it with a known concentration of recombinant sulfotransferase, radiolabeled substrate, co-factor PAPS, ATP, and MgCl~2~, suspended in a protease inhibitor cocktail. Importantly, the use of a recombinant protein OXA activation assay demonstrates the differences in OXA activation between enzymes without any effects from endogenous inhibitors or enhancers. OXA-activation using the recombinant proteins r*Sm*SULT, r*Sh*SULT and r*Sj*SULT revealed very different results from those using crude worm extracts. We found that proteins from both *S. mansoni* and *S. haematobium* showed comparable levels of activity, while recombinant proteins from resistant *S. mansoni* or *S. japonicum* showed minimal activity ([Fig. 4](#fig4){ref-type="fig"}, [Fig. 5](#fig5){ref-type="fig"}, [Fig. 6](#fig6){ref-type="fig"}, [Fig. 7](#fig7){ref-type="fig"}). These recombinant activation assays suggest that amino acid and structural changes between *Sm*SULT and *Sh*SULT do not explain why OXA kills *S. mansoni* but not *S. haematobium*. However, the results do suggest that structural changes may contribute to the inability of *Sj*SULT to activate OXA and in part for the inability of this drug to kill *S. japonicum*.

These results are broadly consistent with kinetic analyses of sulfotransferase activity in the three species. These experiments demonstrated a 2-fold greater k~cat~/K~m~ value for r*Sm*SULT relative to r*Sh*SULT, but 240-fold greater k~cat~/K~m~ value for r*Sm*SULT relative to r*Sj*SULT ([@bib38]).

To further examine the role of amino acid differences between these three enzymes, we conducted experiments using chimeric recombinant proteins, in which residues were swapped between *Sm*SULT and *Sh*SULT or *Sj*SULT. We predicted that chimeric proteins between *Sm*SULT and *Sh*SULT would not impact OXA activation, because the proteins from each of these species show strong activation activity. This prediction was clearly upheld: the recombinant protein OXA activation assay showed no significant change in the ability of the mutated *S. mansoni* sulfotransferase to activate OXA ([Fig. 4](#fig4){ref-type="fig"}, [Fig. 5](#fig5){ref-type="fig"}, [Fig. 6](#fig6){ref-type="fig"}). These results challenge the hypothesis that *Sh*SULT and *Sj*SULT bind OXA poorly compared to *Sm*SULT put forward by [@bib42] and indicate that changes in the amino acid sequence are not fully responsible for OXA resistance in *S. haematobium* or *S. japonicum* (see below). In fact, a recent study shows similar binding affinities (*K*~D~) for OXA to *Sm*SULT (66 μM) and *Sj*SULT (Kd 59 μM) ([@bib18]). However, for *Sj*SULT it seems that Val139 contributes to the inability of *Sj*SULT to activate OXA. Structural analyses suggested that this mutation would impact enzyme function ([@bib38]). Consistent with this hypothesis, Val139Gly substitution in the r*Sj*SULT protein partially restores OXA activation. Hence, for *S. japonicum* amino acid and associated structural changes do impact OXA activation, consistent with [@bib42] prediction. Furthermore, *Sj*SULT possesses additional active site amino acids Asn140 and Asn153 that substitute for aspartate and threonine/serine, respectively ([Fig. 3](#fig3){ref-type="fig"}D). While not predicted to abrogate OXA binding, the two additional substitutions may have an added impact on catalytic efficiency if, for example, they affect alignment of OXA substrate for turnover. The previous observation of multiple conformations for OXA binding in the crystal structure of *Sh*SULT gives some insight on this possibility. Multiple binding modes for OXA could impact *Sh*SULT catalytic efficiency and its Tyr54 substitution for *Sm*SULT active site Phe39 plays a role in the binding position ([@bib38]) Notably, *Sj*SULT also has a Tyr39 at the *Sm*SULT Phe39 position and may therefore experience a similar impact to OXA catalysis as a result.

4.2. What other factors explain low OXA activation in *S. Haematobium* and *S. japonicum* {#sec4.2}
-----------------------------------------------------------------------------------------

Recombinant r*Sh*SULT activates OXA effectively, so it is unclear why OXA treatment does not kill adult *S. haematobium*. We proposed two hypotheses to explain the poor killing activity: (i) substances within homogenates of *S. haematobium* might inhibit or detoxify OXA and (ii) amounts of *Sh*SULT in *S. haematobium* homogenates may be too low to effectively sulfate OXA.

To test the first hypothesis we conducted a titration experiment in which whole worm extract from sensitive *S. mansoni,* HR, E142del and *S. haematobium* were supplemented with r*Sm*SULT at varying concentrations. At high concentrations -- from 1 μM to 100 nM of r*Sm*SULT -- all of the extracts activated OXA about equally. However, when less than 10 nM of r*Sm*SULT was added, the E142del extract showed roughly half the levels of OXA activation as *S. mansoni* extract but the *S. haematobium* extract measured at background ([Fig. 9](#fig9){ref-type="fig"}). These results suggest that an inhibitory component in *S. haematobium* extract might exist to prevent enough OXA sulfation or prevent the sulfated OXA product from exerting its toxic reactivity. We can speculate for example, that the inhibitory component, if it exists, could be a part of a *S. haematobium* or *S. japonicum* detoxification process that converts OXA to a product (as in oxidation) that the sulfotransferase will not use as a substrate. Another possibility is that the sulfated OXA product is detoxified in *S. haematobium* or *S. japonicum* before it kills the worms. If *S. mansoni* has a similar inhibitory component, the *Sm*SULT may simply overcome such a process with a sufficient catalytic efficiency to produce a large enough pool of sulfated OXA to kill the worm unlike the less efficient *Sh*SULT ([Fig. 9](#fig9){ref-type="fig"}). Enzyme efficiency cannot be ruled out as a factor for OXA resistance in *S. haematobium.* This experiment provides some suggestion that inhibition may contribute to the poor killing of *S. haematobium* by OXA.

5. Conclusions {#sec5}
==============

Our results rule out the possibility that active site sequence variation between schistosome species abrogates OXA binding for *S. haematobium*, but this remains a contributory factor for *S. japonicum*. However, differences in sulfotransferase enzyme efficiency, variation in detoxification processes between species, and differences in sulfotransferase concentration remain possible explanations for species-specific resistance and may be interdependent in establishing OXA toxicity. Therefore, one answer to the question is that OXA kills *S. mansoni* but not *S. haematobium* or *S. japonicum* because it does not fit into the SULT binding pocket productively and does not get activated to a sufficiently toxic level.

Schistosomiasis is a neglected tropical disease which disproportionately affects poor communities in developing nations. While the current drug, PZQ, is effective and extraordinarily economical there is no second line drug to turn to when mass chemotherapy causes enough selective pressure for resistance to sweep through the pathogen parasite population. The recently elucidated mechanism of action for an older drug, OXA, has created an exploitable opening for directed drug development ([@bib18]; [@bib19]; [@bib38]). A new generation of drugs are being developed using a rational approach to drug design ([@bib24]; [@bib19]; [@bib30]; [@bib3]).
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